Results 161 to 170 of about 347,205 (251)

A Chemically Defined Four-Component Self-Adjuvanting Tn Vaccine Activating Mincle, FcγR, and CD206 for Enhanced Antitumor Immunity. [PDF]

Adv Sci (Weinh)
Ming W, Zhang R, Li X, Li G, Niu Y, Yang D, Luo X, Liao J, Liu Z, Liao G.   +9 more
europepmc   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

Advanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen, Xinying Fu, Wenqian Dong, Xiaobei Deng, Simin Chen, Fujun Wang, Jian Zhao, Shiqun Shao, Liqiang Fan, Jingyu Zhang, Lixin Zhang   +10 more
wiley   +1 more source

Post-marketing safety surveillance of Haemophilus influenzae Type b conjugate vaccine in children aged 3 months to 5 years in Jiangsu, China. [PDF]

Hum Vaccin Immunother
Zhou Y, Tang R, Wei M, Peng X, Shen R, Li J.   +5 more
europepmc   +1 more source

Immune Checkpoint Inhibitor as a Fifth Component of Lipid Nanoparticles Enables Lymph Node‐Targeting and Augments mRNA Vaccine Efficacy

Advanced Science, EarlyView.
Here, a PDL1 inhibitor is employed as a fifth component to modify lipid nanoparticles (LNPs). PDL1 inhibitor‐loaded LNPs show enhanced lymph node targeting, resulting in greater lymph node expansion, immune cell infiltration, and improved mRNA vaccine efficacy. This fifth component LNP could be a novel platform for mRNA vaccines.
Minki Ha, Jaehyun Kim, Seyoung Kim, Gonna Somu Naidu, Sungchan Cho, Seok‐Beom Yong   +5 more
wiley   +1 more source

The mutual effects on safety and immunogenicity of combined vaccination with 15-valent pneumococcal conjugate vaccine and adsorbed acellular DPT in 3-month healthy infants: A randomized, open-label, controlled, phase III clinical trial. [PDF]

Hum Vaccin Immunother
Lu-Lu P, Hong-Ze M, Zhao G, Min-Jie L, Wen-Jian F, Ya-Nan L, Wang B, Shao-Xin W, Shi G, Li-Na G, Li B, Ying Z, Lin D, Qi L.   +13 more
europepmc   +1 more source

Engineered Allosteric Biosensor for In Situ DNA Glycosylase Detection in Neuroblastoma Risk Stratification and Drug Resistance Monitoring

Advanced Science, EarlyView.
An engineered allosteric biosensor (UUU‐DZ‐tFNA) was developed, in which UDG specifically recognizes and activates a DNAzyme to achieve signal cycle amplification in a sequentially activatable mode. UUU‐DZ‐tFNA achieves in situ UDG detection across multiple biological levels and facilitates risk stratification and drug resistance monitoring of NB ...
Yaqing Lu, Yingyu Zhang, Xianwei Zhang, Mengxin Zhang, Fei Zhang, Jushan Sun, Yahui Yang, Kangbo Liu, Peng Wang, Shuying Luo, Wancun Zhang   +10 more
wiley   +1 more source

Podcast: Immune Persistence After Primary Vaccination with MenQuadfi. [PDF]

Infect Dis Ther
Rämet M, Simon M.
europepmc   +1 more source

Degrading GPX4 via Biomimetic Nanoparticle‐Mediated In Situ Synthesis of Deep‐Learning‐Designed Binder‐Degron Chimeras for Prostate Cancer Therapy

Advanced Science, EarlyView.
A deep‐learning‐designed binder is fused to a combinatorial degron to create a binder‐degron chimera (bdC) that recruits the CUL2‐RING ubiquitin ligase complex. Encapsulation in a prostate‐cancer‐targeted, CD47‐camouflaged nanocarrier enables tumor‐specific in situ bdC expression, triggering GPX4 degradation and ferroptosis, thereby establishing a ...
Si‐Han Zhang, Ye An, Na Zeng, Mei‐Cheng Liu, Jian‐Xuan Sun, Xi Gong, Jin‐Zhou Xu, Shao‐Gang Wang, Qi‐Dong Xia   +8 more
wiley   +1 more source

Immunogenicity of DTaP-IPV-Hib and MenC vaccines in the UK when administered with a 13-valent pneumococcal conjugate vaccine

, 2008
Snape, M., Layton, H., Heath, P.T., Dymond, S., Klinger, C., Gruber, W., Baker, S., Galiza, E., Daniels, E., Pestridge, S., Faust, S.N., Tansey, S., Scott, D., John, T., Finn, A., Pollard, A.   +15 more
core   +1 more source

Chimeric Pathogen-Associated Molecular Patterns (PAMPs) as Vaccine Adjuvants. [PDF]

Vaccines (Basel)
Potter BM, Weth AF, Dangerfield EM, Timmer MSM, Stocker BL.   +4 more
europepmc   +1 more source